Evidence map›Paper›PMID 31407257›Full record

ArticleInternational journal of hematology2019

Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients.

Hajime Yasuda, Miyuki Tsutsui, Jun Ando, Tadaaki Inano, Masaaki Noguchi, Yuriko Yahata, Masaru Tanaka, Yutaka Tsukune, Azuchi Masuda, Shuichi Shirane and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Exploring the molecular mechanisms between lymphoma and myelofibrosis.American journal of translational research · 2024
    Review
  5. American journal of nuclear medicine and molecular imaging · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Hajime YasudaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. hyasuda@juntendo.ac.jp.ORCID http://orcid.org/0000-0002-2896-7737
Miyuki TsutsuiDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Tadaaki InanoDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Yuriko YahataDivision of Hematology, Department of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan.
Masaru TanakaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Yutaka TsukuneDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Azuchi MasudaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Shuichi ShiraneDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kyohei MisawaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Akihiko GotohDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Eriko SatoDivision of Hematology, Department of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan.
Nanae AritakaDivision of Hematology, Department of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan.
Yasunobu SekiguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Keiji SugimotoDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Juntendo University · JPJuntendo University Nerima Hospital · JPJuntendo University Urayasu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin B6 (VB6) deficiency contributes to oncogenesis and tumor progression in certain cancers, and is prevalent in cancer patients in general. VB6 is also an essential element of heme synthesis, and deficiency can lead to anemia. Primary myelofibrosis (PMF) and secondary myelofibrosis (sMF) are myeloproliferative neoplasms often presenting with anemia along with other cytopenias. We performed a prospective study to determine whether PMF and sMF patients suffer from VB6 deficiency, and whether VB6-deficient patients show improvement of anemias with VB6 supplementation. Twelve PMF patients and 11 sMF patients were analyzed. A total of 16 of 23 patients (69.6%) were found to have VB6 deficiency, but VB6 supplementation with pyridoxal phosphate hydrate did not elevate hemoglobin levels in deficient patients. None of the patients presented with vitamin B12, iron, or copper deficiencies. Four patients showed serum folate levels below the lower limit of normal and eight patients showed serum zinc levels below the lower limit of normal; however, these deficiencies were marginal and unlikely to contribute to anemia. Compared to VB6-sufficient patients, VB6-deficient patients showed significantly lower serum folate levels and higher serum copper levels. Studies elucidating the relationship of VB6 deficiency and etiology of PMF/sMF are warranted.

Indexed as

AdultAnemiaCopperFemaleFolic AcidHumansMaleMiddle AgedPrevalencePrimary MyelofibrosisProspective StudiesPyridoxal PhosphateVitamin B 6 DeficiencyCopperFolic AcidPyridoxal PhosphateAnemiaCancerMyelofibrosisOncogenesisVitamin B6 deficiency

Identifiers

PMID31407257
OpenAlexW2967106908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.